[{"orgOrder":0,"company":"Biomm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biomm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biomm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Not Applicable"},{"orgOrder":0,"company":"Biomm","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin and Biomm Enter into a Distribution and Marketing Agreement for Pegfilgrastim in Brazil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Biomm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biomm \/ Lupin","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Lupin"},{"orgOrder":0,"company":"Biomm","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara\u00ae Biosimilar","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Biomm","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biomm \/ Biomm","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Biomm"},{"orgOrder":0,"company":"Biomm","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Partners Biomm to Commercialise Diabetes Drug in Brazil","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biomm","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomm \/ Biomm","highestDevelopmentStatusID":"12","companyTruncated":"Biomm \/ Biomm"}]